X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS PANACEA BIOTECH DR. DATSONS LABS/
PANACEA BIOTECH
 
P/E (TTM) x -10.9 171.2 - View Chart
P/BV x 0.2 3.8 4.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 DR. DATSONS LABS   PANACEA BIOTECH
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
PANACEA BIOTECH
Mar-14
DR. DATSONS LABS/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs126149 84.5%   
Low Rs3182 37.5%   
Sales per share (Unadj.) Rs133.084.1 158.1%  
Earnings per share (Unadj.) Rs0.2-18.3 -0.8%  
Cash flow per share (Unadj.) Rs6.6-6.7 -98.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs128.883.7 153.9%  
Shares outstanding (eoy) m31.6661.25 51.7%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.61.4 42.9%   
Avg P/E ratio x516.1-6.3 -8,180.6%  
P/CF ratio (eoy) x11.8-17.2 -68.7%  
Price / Book Value ratio x0.61.4 44.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m2,4777,074 35.0%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m561,449 3.9%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m4,2115,154 81.7%  
Other income Rs m79100 78.9%   
Total revenues Rs m4,2895,254 81.6%   
Gross profit Rs m569-766 -74.2%  
Depreciation Rs m204711 28.7%   
Interest Rs m4301,503 28.6%   
Profit before tax Rs m13-2,881 -0.4%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m-2-6 31.6%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m617 36.3%   
Profit after tax Rs m5-1,121 -0.4%  
Gross profit margin %13.5-14.9 -90.8%  
Effective tax rate %48.0-0.6 -8,235.4%   
Net profit margin %0.1-21.8 -0.5%  
BALANCE SHEET DATA
Current assets Rs m6,8523,810 179.8%   
Current liabilities Rs m6,7118,365 80.2%   
Net working cap to sales %3.3-88.4 -3.8%  
Current ratio x1.00.5 224.2%  
Inventory Days Days161156 103.3%  
Debtors Days Days31867 473.7%  
Net fixed assets Rs m3,67314,480 25.4%   
Share capital Rs m31761 516.5%   
"Free" reserves Rs m3,761903 416.5%   
Net worth Rs m4,0785,127 79.5%   
Long term debt Rs m1,6715,832 28.7%   
Total assets Rs m12,63319,433 65.0%  
Interest coverage x1.0-0.9 -112.3%   
Debt to equity ratio x0.41.1 36.0%  
Sales to assets ratio x0.30.3 125.7%   
Return on assets %3.42.0 175.3%  
Return on equity %0.1-21.9 -0.5%  
Return on capital %7.73.6 211.0%  
Exports to sales %22.924.5 93.4%   
Imports to sales %14.310.2 140.4%   
Exports (fob) Rs m9641,264 76.3%   
Imports (cif) Rs m602525 114.7%   
Fx inflow Rs m9641,539 62.6%   
Fx outflow Rs m607942 64.4%   
Net fx Rs m357597 59.8%   
CASH FLOW
From Operations Rs m1,345599 224.4%  
From Investments Rs m-2,256-438 515.1%  
From Financial Activity Rs m-1,200-303 396.5%  
Net Cashflow Rs m-2,111-141 1,493.8%  

Share Holding

Indian Promoters % 4.5 74.5 6.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.6 -  
FIIs % 1.4 1.3 103.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 23.6 398.7%  
Shareholders   20,807 10,259 202.8%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   VENUS REMEDIES  ORCHID PHARMA LTD  PFIZER  J.B.CHEMICALS  SHASUN PHARMA  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

Khadim India Ltd. (IPO)

Oct 31, 2017

Should you subscribe to the IPO of Khadim India Ltd?

Mahindra Logistics Ltd. (IPO)

Oct 28, 2017

Should you subscribe to the IPO of Mahindra Logistics Ltd?

Godrej Agrovet Ltd. (IPO)

Oct 4, 2017

Should you subscribe to the IPO of Godrej Agrovet Limited?

Matrimony.com (IPO)

Sep 11, 2017

Should you subscribe to the IPO of Matrimony.com?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS